2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic
Abstract The coronavirus disease 2019 (COVID-19) is an infectious disease caused by
severe acute respiratory syndrome coronavirus 2 that has significant implications for the …
severe acute respiratory syndrome coronavirus 2 that has significant implications for the …
[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
2018 ESC/EACTS Guidelines on myocardial revascularization
FJ Neumann, M Sousa-Uva, A Ahlsson… - European heart …, 2019 - academic.oup.com
always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …
websites. The National Societies of the ESC are encouraged to endorse, translate, and …
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary …
Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …
treatment for patients undergoing percutaneous coronary intervention. The availability of …
2018 ESC/EACTS Guidelines on myocardial revascularization
M Sousa-Uva, FJ Neumann, A Ahlsson… - European Journal of …, 2019 - academic.oup.com
These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Modulation of the biochemical composition of the tumour microenvironment is a new frontier
of cancer therapy. Several immunosuppressive mechanisms operate in the milieu of most …
of cancer therapy. Several immunosuppressive mechanisms operate in the milieu of most …
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS …
CJ Kim, MW Park, MC Kim, EH Choo, BH Hwang… - The Lancet, 2021 - thelancet.com
Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …
Bleeding avoidance strategies in percutaneous coronary intervention
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …